TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20082714
Drug: exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: exercise therapy + usual care
Study: 20591139
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) + usual care
Study: 12232494
Drug: Fasting (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting (250 kcal; 3 l fluid intake/day) without mineral supplements (n = 103)
Study: 12232494
Drug: Fasting (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting (250 kcal; 3 l fluid intake/day) with mineral supplements (3 x 2 to 3 x 3 Bullrich's Vital) (n = 106)
Study: 10421283
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of furosemide therapy
Study: 1288904
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 2 mg.kg‐1 (Group B)
Study: 1288904
Drug: Ranitidine liquid
Normalized name: ranitidine Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine liquid 2 mg.kg‐1 (Group D)
Study: 3908214
Drug: Changing-scheme (adriamycin/cisplatinum–vincristine/cyclophosphamide–high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changing-scheme (adriamycin/cisplatinum–vincristine/cyclophosphamide–high dose methotrexate)
Study: 27131984
Drug: Two short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two short implants
Study: 27131984
Drug: Three short
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three short implants
Study: 27131984
Drug: Four short
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four short implants
Study: 22381164
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in SES stratum (2,735 patients)
Study: 22381164
Drug: Non-statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin therapy in SES stratum (2,294 patients)
Study: 22381164
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in BMS stratum (2,576 patients)
Study: 22381164
Drug: Non-statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin therapy in BMS stratum (2,616 patients)
Study: 20181456
Drug: Well-Being Therapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well-Being Therapy (WBT)
Study: 16219435
Drug: Menthol penetration-enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol penetration-enhanced tetracaine gel (4% tetracaine in carbomer vehicle)
Study: 16219435
Drug: Non-penetration-enhanced tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-penetration-enhanced tetracaine gel (4% tetracaine in carbomer vehicle)
Study: 12114420
Drug: NSC 655649
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSC 655649 single-dose format (step 1)
Study: 7595698
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX) with cranial radiation (CRT)
Study: 7595698
Drug: Conventional-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional-dose methotrexate (CD-MTX)
Study: 7595698
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients (regardless of treatment)
Study: 22907764
Drug: Lowest circulating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lowest circulating CD34(+)KDR(+) in SC rs753482AC+CC
Study: 19674382
Drug: Algorithm-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided treatment (AGT)
Study: 11282170
Drug: IFN-beta1a therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta1a therapy
Study: 9041233
Drug: MK-591 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-591 12.5 mg taken twice daily
Study: 7696378
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg (R,S)‐propranolol.HCl
Study: 7696378
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg (S)‐propranolol.HCl
Study: 7696378
Drug: (S)‐propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)‐propranolol (20 mg)
Study: 7696378
Drug: (R)‐propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)‐propranolol (40 mg)
Study: 3653122
Drug: Diltiazem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (25 mg i.v. single dose)
Study: 28274169
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 10 mg/kg once a day for the first three days of life plus moderate hypothermia
Study: 29027817
Drug: 600,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600,000 IU of vitamin D3 (Cholecalciferol) over 10 days in a dose of 60,000 IU/day
Study: 23690366
Drug: Annexin A5
Normalized name: Annexin A5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annexin A5 anticoagulant activity
Study: 23690366
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with SLE and positive anti-DI antibodies
Study: 15930485
Drug: 1.52 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.52 g/day DHA from capsules containing DHA-rich algal triglycerides
Study: 6367578
Drug: Probucol and
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol and colestipol combination
Study: 6367578
Drug: Probucol alone
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol alone or in combination
Study: 24029016
Drug: 1.5‐s stimulus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5‐s stimulus response (R[L])
Study: 22551482
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose femoral nerve block (30mL of 0.5% ropivacaine)
Study: 20660678
Drug: DRV/r 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r 600/100 mg BID plus RFB 150 mg QOD
Study: 20660678
Drug: DRV/r 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r 600/100 mg BID
Study: 10214002
Drug: Group sequential
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group sequential monitoring
Study: 7043754
Drug: Mianserin 30
Normalized name: mianserin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 30 mg (increased to 60 mg from week 2)
Study: 11834238
Drug: 6% cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% cellulose sulfate gel (2.5 mL and 5.0 mL doses)
Study: 11834238
Drug: 6% cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% cellulose sulfate gel (2.5 mL)
Study: 11834238
Drug: All products
Normalized name: All Clear Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All products (6% cellulose sulfate gel, Conceptrol, K-Y jelly)
Study: 7506854
Drug: PSA values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA values alone with a cutoff of 10 ng/mL at baseline and 5 ng/mL after twelve months of treatment
Study: 1167048
Drug: Topical methenamine
Normalized name: Methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical methenamine gel stick
Study: 31726894
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of DNX-2401 followed by surgical resection 14 days later with a second injection into the resection cavity
Study: 31726894
Drug: DNX-2401 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNX-2401 treatment
Study: 26308291
Drug: Pro‐En (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro‐En (21 g of leucine‐enriched whey protein with carbohydrate (9 g) and fat (3 g))
Study: 26308291
Drug: Pro (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro (21 g of leucine‐enriched whey protein without carbohydrate and fat)
Study: 16595786
Drug: Home care
Normalized name: Alpha Dent Home Care 0.4% Fluoride Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home care nurse-directed treatment strategy
Study: 16595786
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care physician-directed treatment
Study: 12411756
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline for 24 h (1 ml/kg/h) beginning 12 h prior to catheterization
Study: 12411756
Drug: Unrestricted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrestricted oral fluids
Study: 8474062
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 10 mg im on Day 0, no corticosteroid (Group 1)
Study: 8474062
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 10 mg im on Day 0, prednisolone 15 mg/day per os from D-3 (Group 2)
Study: 8474062
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 10 mg im on Day 0, long-term prednisolone treatment 15 mg/day (Group 3)
Study: 23925581
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive physical therapy (CDT) including skin care, manual lymphatic drainage, compression bandages, compression garments, and exercises, n = 15
Study: 23925581
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive physical therapy (CDT) combined with an intermittent pneumatic compression pump, n = 16
Study: 23780502
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg film-coated tablets
Study: 30027002
Drug: Montelukast 5
Normalized name: montelukast 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5 mg chewable tablets
Study: 15582309
Drug: 600-mg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg loading dose of clopidogrel for 3 to 6 h
Study: 11179984
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice daily + Amoxicillin 750 mg twice daily
Study: 9067694
Drug: Neoral (microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (microemulsion oral formulation of cyclosporine A)
Study: 9067694
Drug: Sandimmune SGC
Normalized name: Sandimmune
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune SGC (oral cyclosporine A preparation)
Study: 8453694
Drug: Cyclophosphamide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (1.5 g/m2)
Study: 8453694
Drug: Ifosfamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (5 g/m2)
Study: 3544649
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg buprenorphine epidurally
Study: 3544649
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg buprenorphine epidurally
Study: 22101161
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 15 mg
Study: 27459533
Drug: Gliclazide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (80 mg twice daily)
Study: 24825262
Drug: 300,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300,000 IU of oral vitamin D3 (Group 1; n=38)
Study: 24825262
Drug: 600,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600,000 IU of oral vitamin D3 (Group 2; n=38)
Study: 20616970
Drug: Community-directed intervention
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-directed intervention (CDI) including vitamin A supplementation, insecticide-treated nets, home management of malaria, and short-course, directly-observed treatment for tuberculosis patients.
Study: 18396744
Drug: 80 mL
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mL of NaP (two 40 mL doses separated by 24 h)
Study: 26613214
Drug: Later prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later prophylactic INSURE with surfactant administration at the 15th minute after birth
Study: 23159770
Drug: PegIFNα‐2b (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα‐2b (0.5 μg/kg/week)
Study: 26985045
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation during saline infusion
Study: 25033643
Drug: Analgesic drug
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic drug treatment
Study: 18823760
Drug: Fixed versus
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed versus flexible dose design
Study: 17922880
Drug: AIR Insulin
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIR Insulin after 4-week smoking abstinence
Study: 17922880
Drug: AIR Insulin
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIR Insulin after smoking one cigarette with NRT
Study: 1767251
Drug: Phenoxymethylpenicillin dosed
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin dosed twice daily
Study: 29673262
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy with exercise
Study: 29673262
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy without exercise
Study: 24828024
Drug: Vitamin D₃
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D₃ supplementation (20 μg/d)
Study: 7862896
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg ethanol mixed into a drink of caffeine-free cola
Study: 31539025
Drug: Preoperative volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative volume replacement therapy (VRT) - 1 ml/kg/h of Hartmann's solution for 12 hours
Study: 26380441
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (XI mimetic agent, 100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days)
Study: 24377214
Drug: Half-needling technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-needling technique combined with moxa stick therapy
Study: 8425624
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (12 IU/d)
Study: 28437264
Drug: MgSO4 50
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 50 mg/kg intravenously for 10 min, followed by a continuous infusion of 15 mg/kg/h during surgery
Study: 12924170
Drug: Two placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets a day
Study: 12924170
Drug: One placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet a day
Study: 21388442
Drug: exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: exenatide 10 μg twice daily
Study: 18513453
Drug: Amoxicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (50 mg/kg/d BD)
Study: 10896693
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I (IGF-I) immunoreactivity in skin of ALS patients
Study: 8941104
Drug: Carvedilol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (n = 133; target dose, 25 to 50 mg BID)
Study: 1631473
Drug: Various medical
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various medical and surgical treatments for endometriosis and medically assisted fertilization (IVF)
Study: 24100150
Drug: High-dose rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rate brachytherapy (HDR-BT) with 2 × 8.5 Gy after external beam radiotherapy (EBRT) of 35.75 Gy in 13 fractions
Study: 24100150
Drug: Minimum D₉₀
Normalized name: sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum D₉₀ of 108% of the prescribed dose
Study: 16052573
Drug: Cyclophosphamide (CYC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (CYC), 2 mg/kg/day
Study: 7857502
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract LI 160 (3 x 300 mg daily)
Study: 7857502
Drug: Imipramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (3 x 25 mg daily)
Study: 25806400
Drug: 300 mcg
Normalized name: Lymphir 300 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mcg spinal morphine and 1 gram acetaminophen every 6 hours for 24 hours postoperatively
Study: 25806400
Drug: 150 mcg
Normalized name: kelp 150 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mcg spinal morphine and placebo tablets
Study: 16088297
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with Balsamodendron mukul (1.5 g/d) and nifedipine (10 mg/d)
Study: 2222103
Drug: Cholesterol-lowering agents
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering agents
Study: 31571243
Drug: Delayed periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed periodontal therapy (control group, n=46)
Study: 28930174
Drug: Capsaicin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (4 mg daily)
Study: 28930174
Drug: Control (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.05 mg daily)
Study: 25369588
Drug: Multiparametric staining
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiparametric staining using CFSE and glycophorin A antibody
Study: 25369588
Drug: Multiparametric staining
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiparametric staining using CFSE, glycophorin A antibody, and annexin V
Study: 21747355
Drug: Reference atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference atorvastatin (RA)
Study: 21747355
Drug: Generic atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic atorvastatin (GA)
Study: 10426160
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg orally once a day for 4 days
Study: 29058821
Drug: Ledipasvir (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (120 mg)
Study: 25875447
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g dried ginger root powder (morning and afternoon intake)
Study: 23596262
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of praziquantel (first dose followed by a second dose 2 weeks later)
Study: 20360498
Drug: Water‐soluble lubricating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water‐soluble lubricating gel alone (control)
Study: 10793541
Drug: 2% carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% carteolol hydrochloride (30 microliters, twice daily for 7 days)
Study: 21293243
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 6) plus Paclitaxel (200 mg/m²) on day 1 (CP)
Study: 21293243
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m²) plus Vinorelbine (25 mg/m²) on days 1 and 8 (GV)
Study: 8466265
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEpo) 50 to 150 U administered subcutaneously twice a week from 7 days of age until discharge
Study: 21557378
Drug: Medication Adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Adherence Questionnaire (MAQ)
Study: 29807806
Drug: Drug Attitude
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug Attitude Inventory (DAI)
Study: 17712244
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg/day for the first week and 20 mg/day thereafter)
Study: 17712244
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Placebo (CDRS‐R and MADRS)
Study: 14733787
Drug: Intra-amniotic administration
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic administration of pulmonary surfactant (PS)
Study: 2843722
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone (200 mg t.i.d.)
Study: 21632509
Drug: Paclitaxel/carboplatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/carboplatin with PF-3512676 (0.2 mg/kg subcutaneous on days 8 and 15)
Study: 16393305
Drug: Placebo (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (without L. plantarum 299v)
Study: 15341559
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg/d) and vitamin D (400-600 IU/d) supplements
Study: 11146898
Drug: Once-a-day administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day administration of interferon-alpha
Study: 8856002
Drug: Fluoxetine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, 20 mg daily
Study: 9575014
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Placebo
Study: 1627944
Drug: wuzi yanzong
Approvals — FDA: no, EMA: no, PMDA: no
Description: wuzi yanzong solution (WYS)
Study: 29370992
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, then nivolumab monotherapy)
Study: 26282726
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg (D110)